C4 Therapeutics, Inc.

NasdaqGS:CCCC 주식 리포트

시가총액: US$418.3m

C4 Therapeutics 경영진

경영진 기준 점검 4/4

C4 Therapeutics CEO는 Andrew Hirsch, Sep2020 에 임명되었습니다 의 임기는 5.92 년입니다. 총 연간 보상은 $2.94M, 23.6% 급여 및 76.4% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $459.70K 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.7 년과 8.1 년입니다.

핵심 정보

Andrew Hirsch

최고경영자

US$2.9m

총 보수

CEO 급여 비율23.63%
CEO 재임 기간6yrs
CEO 지분 보유율0.1%
경영진 평균 재임 기간5.7yrs
이사회 평균 재임 기간8.1yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Sep 05

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts

Summary C4 Therapeutics is rated Hold, with valuation hinging on the Phase 2 success of its lead asset, cemsidomide. CCCC holds $300.4 million in cash, providing runway through late 2028 and supporting ongoing clinical and partnered programs. The calculated fair value per share is $3.32, below the current $3.71 price, reflecting significant risk if cemsidomide fails. Phase 2 MOMENTUM trial data in late 2027 is the critical catalyst; success could raise fair value to $5.32 per share. Read the full article on Seeking Alpha
분석 기사 • Aug 14

Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) just released its latest quarterly results and things are looking bullish...
분석 기사 • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
분석 기사 • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
분석 기사 • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
분석 기사 • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
분석 기사 • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
분석 기사 • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
분석 기사 • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
분석 기사 • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
분석 기사 • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
분석 기사 • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
분석 기사 • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
분석 기사 • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
분석 기사 • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

CEO 보수 분석

Andrew Hirsch의 보수는 C4 Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Jun 30 2026n/an/a

-US$101m

Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$3mUS$695k

-US$105m

Sep 30 2025n/an/a

-US$119m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$103m

Dec 31 2024US$5mUS$665k

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

보상 대 시장: Andrew의 총 보수(USD2.94M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.41M) 수준입니다.

보상과 수익: Andrew의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Andrew Hirsch (55 yo)

6yrs
재임 기간
US$2,940,975
보수

Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...

리더십 팀

이름직위재임 기간보수지분
Andrew Hirsch
CEO, President & Director6yrsUS$2.94m0.11%
$ 459.7k
Kenneth Anderson
Co-Founderno dataUS$85.50k0.29%
$ 1.2m
Kendra Adams
Principal Accounting Officer3yrsUS$1.48m0.037%
$ 153.6k
Leonard M. Reyno
Chief Medical Officer3.2yrsUS$1.64m0.027%
$ 113.6k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Courtney Solberg
Senior Manager of Investor Relationsno data데이터 없음데이터 없음
Kelly Schick
Chief People Officer5.7yrs데이터 없음0.032%
$ 132.1k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development10.5yrs데이터 없음데이터 없음
Christopher Nasveschuk
Senior Vice President of Chemistry5.7yrs데이터 없음데이터 없음
Roy Pollock
Senior Vice President of Biological Sciences7.6yrs데이터 없음데이터 없음
Mayra Reyes-Armour
Senior Vice President of Technical Operations5.7yrs데이터 없음데이터 없음
Scott Boyle
Chief Business Officer4.7yrsUS$3.91m0.031%
$ 128.5k
5.7yrs
평균 재임 기간
52yo
평균 나이

경험이 풍부한 관리: CCCC의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.7 년).

이사회 구성원

이름직위재임 기간보수지분
Andrew Hirsch
CEO, President & Director5.9yrsUS$2.94m0.11%
$ 459.7k
Kenneth Anderson
Co-Founder10.8yrsUS$85.50k0.29%
$ 1.2m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board9.8yrs데이터 없음데이터 없음
Christopher Bowden
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Steven Hoerter
Independent Director1.8yrsUS$90.31k데이터 없음
Christopher Kirk
Member of Scientific Advisory Board9.8yrs데이터 없음데이터 없음
Ross Levine
Member of Scientific Advisory Board9.2yrs데이터 없음데이터 없음
Ronald H. Cooper
Independent Chairman2.3yrsUS$119.25k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Board7yrs데이터 없음데이터 없음
Scott Armstrong
Member of Scientific Advisory Board9.2yrs데이터 없음데이터 없음
Utpal Koppikar
Independent Director4.5yrsUS$100.50k0.0046%
$ 19.3k
Beni Wolf
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
8.1yrs
평균 재임 기간
55yo
평균 나이

경험이 풍부한 이사회: CCCC의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.1 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/09/11 11:22
종가2026/09/11 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

C4 Therapeutics, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets